Cardiol Therapeutics Inc. SEC filings CRDL

Cardiol Therapeutics Inc. has 188 filings in SEC EDGAR's recent list, going back to Mar 29, 2017. Its latest annual report, Form 40-F, was filed on Mar 31, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Nov 3, 2026. The company's fiscal year ends on December 31.

Form Description Filed Period
SCHEDULE 13G/A Amended ownership over 5% (passive) Sep 23, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) Aug 14, 2026 —
SCHEDULE 13G/A Amended ownership over 5% (passive) May 15, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Jan 30, 2026 —
SCHEDULE 13G Ownership over 5% (passive) Oct 23, 2025 —
SC 13G/A Amended ownership over 5% (passive) Nov 6, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 13, 2024 —
SC 13G/A Amended ownership over 5% (passive) Feb 14, 2023 —
SC 13G/A Amended ownership over 5% (passive) Feb 7, 2022 —
SC 13G Ownership over 5% (passive) Nov 15, 2021 —

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
CRDL (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Ontario, Canada
Headquarters
Oakville, Ontario, Canada
SEC filer status
, Emerging growth company
SEC CIK
1702123

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.